Skip to main content

Renal-Cell Carcinoma

Study 218: Higher Lenvatinib Starting Dose Trended Toward Better Outcomes

BREAKPOINT: Cabozantinib Efficacious After Treatment with First-Line Immunotherapy

Renal-Cell Carcinoma Year in Review Introduction

COSMIC-021: Antitumor Activity with Cabozantinib plus Atezolizumab for Clear-Cell and Non–Clear-Cell Renal-Cell Carcinoma

Belzutifan Shows Promise as a Novel Option for Advanced Renal-Cell Carcinoma

IMmotion150: Atezolizumab plus Bevacizumab Safe and Efficacious in Pretreated Disease

KEYNOTE-146: Lenvatinib plus Pembrolizumab Tolerable and Effective in Treatment-Naïve and Previously Treated Patients with RCC

TIVO-3: Post-Hoc and Subgroup Analyses of Third- and Fourth-Line Tivozanib Treatment Compared with Sorafenib

CheckMate-9ER: Nivolumab plus Cabozantinib Extends Progression-Free Survival and Overall Survival Compared with Sunitinib

CLEAR: Lenvatinib plus Pembrolizumab Improves Progression-Free Survival and Overall Survival versus Sunitinib in First-Line Setting

1
2
3

Page 2 of 3
Results 11 - 20 of 27